Skip to main content

Research Repository

Advanced Search

: A Targeted Approach To Reduce Risk of Blood Clotting in MPN Patients

People Involved

Project Description

A new mechanism has been identified where an intracellular switch, called AMP-activated protein kinase (AMPK) inhibits the function of constitutively active JAK2V617F protein responsible for disease in many patients with MPNs. Based on this observation, we believe AMPK-activating drugs currently used to manage type 2 diabetes to be repurposed to reduce thrombotic complications in MPN patients. Thrombotic complications negatively impact the quality of life and life expectancy of patients with MPNs, a group of three related blood cancers. A new mechanism has been identified by which a widely prescribed class of drugs currently used to treat type 2 diabetes can inhibit a critical cellular pathway in blood vessel walls responsible for bleeding complications in MPN patients. By understanding the molecular mechanisms responsible, we will examine the potential for using these drugs to manage thrombotic complications effectively in MPN patients. It is likely that this collaborative MSc research project between the HYMS Biomedical Institute for Multimorbidity and HUTH Haematology will pump prime substantive applications for external funding as well as provide the student with laboratory and analytical skills important for career progression.

Status Project Live
Value £30,000.00
Project Dates Oct 1, 2023 - Jan 31, 2025

You might also like

LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy Jun 1, 2018 - Feb 28, 2022
Acute leukaemia (AL) is an aggressive but potentially curable cancer that can affect women of childbearing age. When a pregnancy is complicated by a diagnosis of AL, clinicians face a complex dilemma: to balance risking the mother’s survival through... Read More about LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy.

CLL Research Jan 26, 2015 - Dec 31, 2028
Translational research project utilising prospective sample collection from patients attending the Haematology Clinic, Hull university Teaching Hospital Trust, to facilitate research within the University of Hull.

STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL) Jan 1, 2021 - Mar 31, 2031
Chronic lymphocytic leukaemia (CLL) is a cancer that affects the blood and bone marrow. It tends to progress slowly, and is incurable. CLL is the most common leukaemia in adults. The first treatment for CLL is chemotherapy. This is usually given for... Read More about STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL).